NanoString Technologies, Inc. (NSTG) |
| 0.1053 -0.063 (-37.43%) 06-17 16:00 |
| Open: | 0.128 |
| High: | 0.13999 |
| Low: | 0.1025 |
| Volume: | 21,428,464 |
| Market Cap: | 5(M) |
| PE Ratio: | -0.03 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Instruments & Supplies |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 2.05 |
| Resistance 1: | 1.89 |
| Pivot price: | 1.71 |
| Support 1: | 1.64 |
| Support 2: | 1.36 |
| 52w High: | 0.13999 |
| 52w Low: | 0.1025 |
NanoString Technologies, Inc. is a global innovator in scientific instrumentation, designing and producing advanced research tools for genomics and proteomics across the Americas, Europe, the Middle East, and Asia Pacific. Its flagship offering is the nCounter Analysis System, an automated platform renowned for its versatile digital detection and counting capabilities. This system includes both nCounter MAX and FLEX configurations, which integrate a Prep Station for automated liquid handling and sample preparation, alongside a Digital Analyzer. The Analyzer captures data by imaging fluorescent reporters within sample cartridges, then processes this information into usable output files. The company also offers the nCounter SPRINT Profiler, a compact instrument that streamlines liquid handling and digital analysis using a specialized microfluidic cartridge. Complementing its hardware, NanoString provides nSolver Analysis Software, a powerful program enabling researchers to verify, normalize, and interpret their experimental data. Further extending its product portfolio, NanoString supplies customizable CodeSets and pre-designed panels tailored for applications in oncology, immunology, infectious diseases, and neuroscience. Essential Master Kits, containing reagents and plasticware, are also available to facilitate sample setup and processing within their nCounter Prep Station and Digital Analyzer. Additionally, they market Prosigna molecular diagnostic test kits. Looking ahead, NanoString is actively developing the GeoMx DSP system, poised to advance the field of spatial genomics. The company maintains strategic partnerships, including collaborations with Lam Research Corporation for the research and development of Hyb & Seq technologies, and with Celgene Corporation on LymphMark, an in vitro diagnostic for diffuse large B-cell lymphoma. They also work with the Parker Institute for Cancer Immunotherapy to improve CAR-T regimens and patient outcomes across various cancer types. Established in 2003, NanoString Technologies, Inc. operates from its headquarters in Seattle, Washington.
| EPS | -2260000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | -16.099 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -2.00 |
| Return on Assets (ttm) | 145.6 |
| Return on Equity (ttm) | -13.2 |
Mon, 11 Mar 2024
Health care investment firm agrees to acquire NanoString for $220M - The Business Journals
Tue, 03 Oct 2023
A*STAR’s Genome Institute of Singapore, NanoString and Next Level Genomics Establish Joint Lab to Advance Studies of Complex Diseases with Spatial Genomics - Business Wire
Thu, 14 Sep 2023
NanoString to Host Virtual Spatial Genomics Summit September 19 - Business Wire
Mon, 28 Aug 2023
NanoString Appoints Todd Garland as Chief Commercial Officer - Business Wire
Tue, 13 Dec 2022
NanoString’s CosMx Spatial Molecular Imager Recognized by The Scientist Magazine as a Top 10 Innovation of 2022 - Business Wire
Thu, 13 Oct 2022
NanoString and Visiopharm Announce Collaboration to Co-develop Integrated Workflows for GeoMx and AtoMx Spatial Biology Solutions - Business Wire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |